Adverse events possibly related to decitabine priming
| Adverse event . | Grade 1 . | Grade 2 . | Grade 3 . | Total . | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort . | A1 . | B1 . | A2 . | B2 . | A3 . | B3 . | A1 . | B1 . | A2 . | B2 . | A3 . | B3 . | A1 . | B1 . | A2 . | B2 . | A3 . | B3 . | |
| GI | 5 | 3 | 5 | 5 | 5 | 5 | 3 | 4 | 4 | 2 | 1 | 5 | 1 | 3 | 5 | 56 | |||
| Infection | 1 | 2 | 1 | 2 | 1 | 5 | 5 | 3 | 5 | 5 | 5 | 35 | |||||||
| Cardiac | 3 | 2 | 4 | 2 | 3 | 2 | 1 | 2 | 1 | 1 | 21 | ||||||||
| Dermatology | 2 | 4 | 1 | 2 | 2 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 21 | ||||||
| Constitutional | 1 | 3 | 2 | 5 | 2 | 2 | 3 | 1 | 1 | 20 | |||||||||
| Musculoskeletal | 3 | 1 | 2 | 1 | 3 | 1 | 2 | 1 | 14 | ||||||||||
| Respiratory | 1 | 4 | 2 | 3 | 1 | 11 | |||||||||||||
| Neurology | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 10 | |||||||||||
| Hepatobiliary | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 9 | |||||||||||
| Bleeding | 4 | 2 | 1 | 1 | 1 | 9 | |||||||||||||
| Adverse event . | Grade 1 . | Grade 2 . | Grade 3 . | Total . | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort . | A1 . | B1 . | A2 . | B2 . | A3 . | B3 . | A1 . | B1 . | A2 . | B2 . | A3 . | B3 . | A1 . | B1 . | A2 . | B2 . | A3 . | B3 . | |
| GI | 5 | 3 | 5 | 5 | 5 | 5 | 3 | 4 | 4 | 2 | 1 | 5 | 1 | 3 | 5 | 56 | |||
| Infection | 1 | 2 | 1 | 2 | 1 | 5 | 5 | 3 | 5 | 5 | 5 | 35 | |||||||
| Cardiac | 3 | 2 | 4 | 2 | 3 | 2 | 1 | 2 | 1 | 1 | 21 | ||||||||
| Dermatology | 2 | 4 | 1 | 2 | 2 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 21 | ||||||
| Constitutional | 1 | 3 | 2 | 5 | 2 | 2 | 3 | 1 | 1 | 20 | |||||||||
| Musculoskeletal | 3 | 1 | 2 | 1 | 3 | 1 | 2 | 1 | 14 | ||||||||||
| Respiratory | 1 | 4 | 2 | 3 | 1 | 11 | |||||||||||||
| Neurology | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 10 | |||||||||||
| Hepatobiliary | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 9 | |||||||||||
| Bleeding | 4 | 2 | 1 | 1 | 1 | 9 | |||||||||||||
The most common side effects according to system included: GI tract—diarrhea, nausea, constipation, and mucositis; infectious—bacteremia; cardiac—dizziness, hypotension, and chest pain; dermatology—macular erythematous rash; and constitutional—fatigue, insomnia, anxiety, and chills. Biological systems with less than 9 adverse effects, all grade ≤ 2, are not shown. No grade 4 nonhematologic toxicities were observed.